Skip to main content
Oncotarget logoLink to Oncotarget
. 2024 Jun 3;15:354. doi: 10.18632/oncotarget.28580

Retraction: Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma

Mohammad Krayem 1,, Ahmad Najem 1, Fabrice Journe 1,2, Renato Morandini 1, François Sales 1, Ahmad Awada 3, Ghanem E Ghanem 1
PMCID: PMC11146631  PMID: 38829662

This article has been retracted: Multiple internal duplications of western blot images illustrating the data of different experiments have been discovered throughout Figure 3C. In addition, Figure 3C also contains blots images from Figure 2A in an earlier published paper [1]. Therefore, with the agreement of all authors, the Scientific Integrity office at Oncotarget has decided to retract this paper.

Original article: Oncotarget. 2018; 9:31888–31903. 31888-31903. https://doi.org/10.18632/oncotarget.25879

REFERENCES

  • 1. Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib. Eur J Cancer. 2016; 55:98–110. 10.1016/j.ejca.2015.12.002. [DOI] [PubMed] [Google Scholar]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES